<DOC>
	<DOCNO>NCT01894685</DOCNO>
	<brief_summary>Several study indicate mesalazine might preventive effect recurrence adenoma patient without inflammatory bowel disease . As mesalazine limited adverse effect , attractive candidate chemoprevention . In study aim investigate antineoplastic property mesalazine patient sporadic colorectal adenoma .</brief_summary>
	<brief_title>Mesalazine Effects Sporadic Colorectal Adenoma Patients</brief_title>
	<detailed_description>Rationale : Patients sporadic colorectal adenomatous polyp remove polypectomy high rate polyp recurrence carry increase risk development colorectal carcinoma ( CRC ) . Chemoprevention may lower rate adenoma recurrence polypectomy , thereby reduce risk development death CRC . Mesalazine attractive candidate chemoprevention , since even long-term use limited systemic adverse effect gastrointestinal toxicity . In prospective trial trend towards reduce adenoma recurrence observe high risk patient history least 3 sporadic colorectal adenoma treat mesalazine . Identification biologically relevant antineoplastic property mesalazine patient sporadic adenomatous polyp support investigation mesalazine chemopreventive agent colorectal neoplasia sporadic setting . Growth inhibition colonic epithelial cell induction apoptosis inhibition proliferation widely recognize potential mechanism chemoprevention colorectal cancer . In vivo data suggest mesalazine exerts pro-apoptotic anti-proliferative effect normal colorectal epithelial cell . Furthermore , vitro evidence CRC cell mesalazine inhibits Wnt/beta-catenin signalling , early common inappropriately activated pathway colorectal carcinogenesis molecular target chemoprevention . Objective : Evaluate effect mesalazine therapy histologically normal sigmoid rectal mucosa patient high risk recurrent sporadic colorectal adenoma . Primary endpoint : - change apoptotic index treatment compare placebo - change proliferation index distribution proliferate cell crypts treatment compare placebo Secondary endpoint : â€¢ change expression beta-catenin signal pathway component treatment compare placebo Study design : double-blind , randomize placebo-controlled study Study population : 68 patient , age 50-75 year , underwent polypectomy within 6 month study entry , removal 2 colorectal adenomas irrespective size and/or 1 colorectal adenoma least 1 follow feature : diameter least 1 cm endoscopy , proximal localization , high-grade dysplasia villous histology . Intervention : Patients randomize receive 3.0 g mesalazine ( n=34 ) placebo ( n=34 ) daily 6 month double-blinded way . At baseline 6 month treatment , sigmoidoscopy perform five biopsy normal appear sigmoid rectal mucosa collect . Main study parameters/endpoints : The effect treatment mesalazine apoptotic proliferation index relative placebo group .</detailed_description>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>age : 5075 year undergone complete colonoscopy polypectomy removal 2 colorectal adenoma , irrespective size , and/or 1 colorectal adenoma : least 1 cm diameter and/or locate proximal splenic flexure and/or highgrade dysplasia and/or villous histology inflammatory bowel disease familial colorectal cancer syndrome history colorectal carcinoma history surgery large bowel ( except appendectomy ) chronic renal insufficiency chronic hepatic insufficiency allergy salicylates diabetes mellitus ( high risk develop renal disease ) coagulation disorder anticoagulant use , temporarily discontinue ( precludes biopsy take ) asthma prescription use acetylsalicylic acid calcium carbasalate ( high lowdose ) NSAIDs use medicine may interact mesalazine : methotrexate , thiopurines , cyclosporine , coumarin anticoagulant rifampicin</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Colorectal</keyword>
	<keyword>Adenoma</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Mesalazine</keyword>
	<keyword>Chemoprevention</keyword>
</DOC>